2 active not recruiting. 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Active not recruiting 2 |
Follow IFL protocol: new trials by email Literature Review of IFL protocol trials Research Report on IFL protocol
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors ST316, FOLFIRI regimen & bevacizumab, Fruquintinib - Colon Cancer, Metastatic Colon Cancer | Phase 1 | Active not recruiting | Sapience Therapeutics | 130 | 2023-06-05 | 2026-07-22 |
| TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers TTX-080, pembrolizumab, cetuximab - Cancer | Phase 1 | Active not recruiting | Tizona Therapeutics, Inc | 240 | 2020-07-14 | 2026-09-11 |
Adenocarcinoma of Lung (1) · Breast Neoplasms (1) · Carcinoma, Renal Cell (1) · Colonic Neoplasms (1) · Colorectal Neoplasms (1) · Endometrial Neoplasms (1) · Head and Neck Neoplasms (1) · Kidney Neoplasms (1) · Lung Neoplasms (1) · Melanoma (1) · Neoplasm Metastasis (1) · Neoplasms (1) · Ovarian Neoplasms (1) · Prostatic Neoplasms (1) · Squamous Cell Carcinoma of Head and Neck (1)
Sapience Therapeutics (1) · Tizona Therapeutics, Inc (1)
United States (2)